Technology
Health
Biotechnology
Cytokinetics
$14.059876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$14.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.06 (0.43%) As of 1:55 PM EDT today
+$0.06 (0.43%) Today
Why Robinhood?
You can buy or sell Cytokinetics and other stocks, options, ETFs, and crypto commission-free!
About CYTK
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Employees
130
Headquarters
South San Francisco, California
Founded
1997
Market Cap
820.92M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
495.70K
High Today
$14.30
Low Today
$13.93
Open Price
$13.99
Volume
212.75K
52 Week High
$14.30
52 Week Low
$5.75
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America
CYTK News
Price Paid on Robinhood
52% Higher
Right Now
52 Week Low
$5.75
Average Price Paid
$9.22
52 Week High
$10.44
Analyst Ratings
86%
of 7 ratings
Buy
86%
Hold
14%
Sell
0%
CYTK Earnings
-$0.75
-$0.63
-$0.52
-$0.40
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.50 per share
Actual
-$0.56 per share